Venous Thromboembolism and Cancer: Current Issues and Treatment Updates

Donati M.B. . Cancer and thrombosis. Haemostasis. 1994; 4: 128–131.

Heit J.A. , O'Fallon W.M. , Petterson T.M. . Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 4: 1245–1248.

Heit J.A. , Silverstein M.D. , Mohr D.N. . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 4: 809–815.

Sorensen H.T. , Mellemkjaer L. , Olsen J.H. . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 4: 1846–1850.

Hirsh J. , Guyatt G. , Albers G.W. . The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. Chest. 2004: 126: 172S–173S.

Lee A.Y. , Levine M.N. , Baker R.I. . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 4: 146–153.

Monreal M. , Roncales F.J. , Ruiz J. . Secondary prevention of venous thromboembolism: a role for low-molecular-weight heparin. Haemostasis. 1998; 4: 236–243.

Kakkar A.K. , Levine M.N. , Kadziola Z. . Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004; 4: 1944–1948.

Altinbas M. , Coskun H.S. , Er O. . A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 4: 1266–1271.

Lee A.Y.Y. , Rickles F.R. , Julian J.A. . Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 4: 2123–2129.

Holzheimer R.G. . Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH). Eur J Med Res. 2004; 4: 150–170.